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Cardiac mesenchymal cells -often referred to simply as 'fibroblasts' , derived from the Latin fibra (fibre or filament) and the Greek blastos (germ or sprout) -are among the most populous cells of the heart 1, 2 . Fibro blasts are also a cell type most conspicuously linked to heart disease, as they are associated with tissue remod elling that involves fibrosis 1, [3] [4] [5] [6] . Fibrosis contributes to some of the leading causes of sickness and death in the developed world, including the patho physiological con sequences of myocardial infarction (MI) in which myo cytes are replaced by a collagenrich scar, hypertension, diabetes, rheumatic heart disease, hypertrophic cardio myopathy and heart failure, all of which are associated with the patchy or diffuse appearance of excess fibrotic tissue. Surplus collagen, generated by activated fibro blasts known as myofibroblasts, increases the stiffness of the myocardial wall, impeding normal systolic and diastolic mechanical function.
Focal scarring and diffuse fibrosis are independent predictors of the likelihood of developing electrophysio logical disturbances resulting in cardiac arrhythmias 2, 7, 8 . Therefore, inhibiting or reversing fibrosis and its adverse consequences is an established target of many widely used clinical interventions for treating heart disease, including angiotensinconverting enzyme (ACE) inhibitors, aldos terone antagonists, and statins (TABLE 1) . These interven tions may lead to a partial recovery of contractile function through a process known as 'reverse remodelling' and thereby delay the progression towards heart failure.
The individual and societal costs of heart diseases linked to fibrosis are staggering 9 . In the case of ischae mic heart disease alone, the American Heart Association reports that each year approximately 635,000 Americans are hospitalized or die from their first MI. More than half of these survive, but each year around 280,000 patients will go on to suffer subsequent coronary events, leading to further loss of cardiac muscle and additional deposi tion of noncontractile and potentially arrhythmogenic fibrotic tissue. The direct costs arising from ischae mic heart disease in the United States are in excess of US$180 billion per year. Heart failure after MI represents a further annual burden of $20-40 billion.
There is a strong clinical and economic case, there fore, for developing new and effective approaches to targeting cardiac disease processes linked to fibroblast function. This Review considers the origin and roles of fibroblasts, illustrates their involvement in current and emerging clinical interventions, and identifies future targets for basic and applied heart research.
Fibroblasts and adult myocardial homeostasis
In the healthy heart, fibroblasts are the main cell type involved in the formation and maintenance of con nective tissue 1, 3, 10 . Cardiac connective tissue consists of cellular and acellular components, with the acellular extracellular matrix (ECM) providing a flexible scaffold for individual myocytes and for the heart as a whole 11 . This highly organized collagenrich meshwork, which Novel therapeutic strategies targeting fibroblasts and fibrosis in heart disease Robert G. Gourdie 1, 2, 3 , Stefanie Dimmeler 4, 5 and Peter Kohl 6, 7, 8 Abstract | Our understanding of the functions of cardiac fibroblasts has moved beyond their roles in heart structure and extracellular matrix generation and now includes their contributions to paracrine, mechanical and electrical signalling during ontogenesis and normal cardiac activity.
Fibroblasts also have central roles in pathogenic remodelling during myocardial ischaemia, hypertension and heart failure. As key contributors to scar formation, they are crucial for tissue repair after interventions including surgery and ablation. Novel experimental approaches targeting cardiac fibroblasts are promising potential therapies for heart disease. Indeed, several existing drugs act, at least partially, through effects on cardiac connective tissue. This Review outlines the origins and roles of fibroblasts in cardiac development, homeostasis and disease; illustrates the involvement of fibroblasts in current and emerging clinical interventions; and identifies future targets for research and development.
is laid down by fibroblasts, stabilizes the myocardial wall and supports force transmission, but still allows for intricate patterns of tissue deformation 12 . The fibrous skeleton also provides regions that act as barriers and supports; for example, establishing myofascial planes between sheetlets of muscle, reinforcing conduits for blood vessels, separating electrical activation of the atria and ventricles, or insulating bundles of the cardiac conduction system.
The fibrous skeleton of the heart also provides a substrate for tissueengineered repair. In one notable experiment, perfused rodent hearts were decellular ized, leaving the ECM scaffold, including the ECM sur rounding the coronary vascular tree, intact 13 . This ECM scaffold was then repopulated with neonatal myocytes, which -based on the available structural cues -settled to recapitulate a beating, heartlike organ. Although regeneration of a mature heart in toto by this approach remains a distant prospect, initial clinical applications of this method could include use of decellularized ECM patches for surgical repair 14 . These cardiac ECM scaf folds can be repopulated with induced pluripotent stem cells (iPSCs) -raising the prospect of patientspecific reparative therapies 15 . Conceptually, this builds on breakthroughs over the past 10-15 years in the preclini cal and clinical application of decellularized allografts and xenografts for heart valve repair and replacement 16 , including the limitations and challenges associated with such an approach 17 . In addition to the maintenance of connective tissue, cardiac fibroblasts express a wide array of paracrine fac tors and cytokines and have complex biochemical and biophysical interactions with myocytes, thereby influ encing development, growth and functional adaptation of muscle cells to physiological and pathophysiological challenges 1, 3, 5, 18 . Paradoxically, given the aforementioned role of fibrous tissue in insulation, there is evidence for direct electrical communication through heterocellu lar connexin junctions between fibroblasts and myo cytes [19] [20] [21] -interactions that may well have implications for the modulation of electromechanical activity of heart muscle in health and disease 2, 7, 22, 23 . Thus, fibroblasts form physiological signalling hubs, the relevance of which extends well beyond classic roles in the generation and maintenance of mechanically connective but electrically divisive tissue.
Developmental origins of fibroblasts
One of the impediments to developing new mecha nistically based strategies to target fibroblast function in disease has been an incomplete understanding of their multilineage derivation and the potential regu latory interactions between mesenchymal cells of dif fering origins. A characteristic feature of fibroblasts is the ability to generate ECM; however, this functional capacity is frequently left unconfirmed when classifying nonmyocytes in vitro or in vivo. Nonetheless, consid erable progress has been made over the past 25 years, and the associated new insight is beginning to affect our understanding of the normal and the diseased heart (FIG. 1) .
The proepicardium -a sproutlike cluster of extra cardiac cells that first comes to prominence at the loopedtube stage of cardiac development 24 ,25 -provides the source for a thin mantle of epicardial epithelium that progressively envelops the embryonic heart 24, 26 . Epithelial-mesenchymal transition (EMT) at the epicardium is the largest initial source of resident interstitial cells 25, 27, 28 (FIG. 2) and may persist as a response pattern to myocardial injury in the adult heart 29 . Recent data suggest that the proepicardium itself is an evolutionary derivative of the primordium of an ancient pronephric glomerulus 30 , suggestive of interesting phylogenetic links between fibrotic processes in kidneys and the heart. Paracrine signalling by fibroblast growth factors (FGFs), bone morphogenetic proteins, retinoic acid, various members of the transforming growth factorβ (TGFβ) family 4, [31] [32] [33] , as well as transcriptional activators, including Wilms tumour protein (WT1) 34 and Tbox proteins (TBX18 and TBX20) 35, 36 , have been identified as early regulators of epicardial EMT. These proteins affect pathways including canonical and non canonical WNT signalling and Hedgehog and retinoic acid signalling, which have downstream effects on gene programmes that regulate intercellular interactions, actin dynamics and cell motility. Following invagination of the mesenchyme from the embryonic epicardium into the myocardium, various signaltransduction and regulatory molecules govern the transition of epicardiumderived cells (EPDCs) into cells with more mature fates, including fibroblasts 5, 6 . These molecules include TGFβ 37, 38 , FGF 39 , platelet derived growth factor (PDGF) 40 , protooncogene tyrosine protein kinase 38 , RHO kinase 41 , integrins 42 , pro teins encoded by popeye domaincontaining genes (such as blood vessel epicardial substance (BVES)) 43, 44 , serum response factor 45 , transcription factor 21 (TCF21) 46, 47 and myocardinrelated factors 48 . There is also evidence from studies in Xenopus laevis that TCF21 functions as a transcriptional repressor to regulate proepicardial cell specification and the correct formation of a mature epithelial epicardium 47 . Pericytes form a distinct cohort of mesenchymal cells that reside at perivascular locations 4 . Pericytes can express stem cell markers (for example, octamerbinding protein 4 (OCT4) and the transcription factor SOX2) 49 and may be progenitor cells capable of selfrenewal and differentiation into more mature mesenchymal and smooth muscle 50 phenotypes. There are unresolved ques tions as to whether pericytes contribute to cardiac fibrotic remodelling 51 . Prominent fibrosis around blood vessels is a feature of many diseases of the heart, and there is evidence for phenotypic variance between quiescent and activated fibroblasts at perivascular and interstitial loci 3, 4 . Mesenchymal cells can also arise in the embryonic myocardium through endothelial-mesenchymal tran sition (EndoMT) of endocardial endothelial cells 52 as well as from migratory populations of neural crest cells 53 (FIG. 2) . Cells of endocardial origin primarily contribute to the developing inlet valves, whereas neural crest derived cells seem to be largely confined to the connective tissue of the great vessels and, possibly, the cardiac out flow tract 54 . Minor populations of fibroblastlike cells that originate from these sources are also resident in homeo static myocardial tissues. Notable in this respect are neural crestderived mesenchymal cells in the atria 55 and around proximal components of the cardiac conduction system 56 . The tissues of the embryonic heart are thus subject to waves of immigration of mesenchymal progenitors from heterogeneous sources, with each of these differ ent populations demonstrating some specificity in their spatiotemporal and, possibly, functional assignments in the developing organ.
Fibroblasts in the adult heart Myofibroblasts. Fibroblasts are changeable in character. A pertinent aspect of this phenotypic variability is the transition of quiescent fibroblasts, through a protomyo fibroblast intermediary stage, into myofibroblasts 1, 3, 5, 6 (FIG . 2) . Pathways involved in the conversion of fibro blasts into myofibroblasts are thought to include TGFβ 57 , endothelin 1 (REFS 6, 58) , angiotensin II (ANGII) 59 and WNT-βcatenin signalling 3, 6 . The gapjunction protein connexin 43 (Cx43) has been found to regulate TGFβ signalling in a nonchanneldependent manner 60 , and knockdown or overexpression of Cx43 inhibits or poten tiates TGFβinduced myofibroblastic phenoconversion, respectively 61 . Other signal transduction pathways impli cated in regulating phenotypic conversion of quiescent fibroblasts into myofibroblasts include the peroxisome proliferatoractivated receptorγ, Jun Nterminal kinase (JNK) and AKT signalling pathways; some effectors of these pathways are also downstream of TGFβ signal ling 1, 5 . The cell membrane protein caveolin 1 (REF. 62 ) and numerous proteins that mediate interactions between cell membrane receptors and the ECM (socalled matricellular proteins) are also involved in regulating myofibroblast trans differentiation. Matricellular pro teins include thrombospodins 63 , secreted protein acidic and rich in cysteine (SPARC) 64 , periostin 65 , tenascin C 66 and extracellular matrixassociated proteins (CCN pro teins, an acronym derived from the first three proteins discovered in this family) 67 . Although their contribution to heart function is evident, the specific roles of each of the matricellular proteins remain poorly characterized, but they probably include the generation of a conducive mechanoenvironment, effects on directed migration, stress fibre formation and the production and/or acti vation of signalling factors (such as TGFβ1) that pro mote the conversion of fibroblasts to myofibroblasts 68 . By contrast, CCN5 (also known as WISP2) may be able to reduce established cardiac fibrosis by inhibiting the generation of, and enhancing the apoptosis of, myo fibroblasts in the heart 69 . Additionally, targeted ablation of periostinexpressing fibroblasts, activated by chronic ANGII exposure, prevents adverse cardiac remodelling in mice 70 . Many of the pathways governing the transition of fibroblasts to myofibroblasts are mechanosensitive [71] [72] [73] and potentially involve stretchactivated ion chan nels and changes in cellular calcium handling [74] [75] [76] . Myofibroblasts are able to generate mechanical force, which is important for scar contraction and remod elling 77 . This is a consequence of the upregulation of proteins involved in coordinated force generation and tension generation, including αsmoothmuscle actin (αSMA), myosins and junctional molecules such as cadherins and Cx43. These cells also have important roles in the active secretion and turnover of collagen and other ECM molecules 10 , and they are responsive to hypoxia, cytokines and signalling molecules associated with the inflammatory milieu, such as TGFβ, tumour necrosis factor (TNF), interleukin2 (IL2) and IL6 (REFS 1, 3, 5, 6, 78) . Activated fibroblasts are a common component of granulation tissue throughout the body, typically peaking in density at 4-6 days postinjury, and their presence is preceded, and possibly regulated, by an increase in tissue macrophages from circulating and resident sources 79, 80 . An interesting difference between wound healing in skin versus in the heart is that cells resembling myofibroblasts seem to persist in cardiac scars 81 (in some cases, for up to 17 years), although it can be difficult to distinguish myofibroblasts from res ident macrophages based on their appearance by elec tron microscopy 82 . The mechanisms for preservation of myofibroblasts in healed postMI scars may be related to the interplay between endothelin, angiotensin and TGFβ signalling. This maintenance of myofibroblasts in the scar postMI is thought to confer mechanical ben efits: murine strains with high densities of myofibro blasts in healed infarcts showed improved ventricular function and reduced propensity for scar expansion and ventricular dilation 83 .
Resident and non-resident mesenchymal cell populations.
The heterogeneous origin and phenotypic variability of fibroblasts pose technical challenges for experimental cell identification. Expressed proteins, including dis coidin domaincontaining receptor 2 (DDR2), peri ostin, vimentin, fibronectin, ectodysplasin A (EDA), WT1, PDGF receptor, TCF21, αSMA and membrane glyco protein THY1 (also known as CD90), are com monly used to identify fibroblasts and myofibroblasts 4 . However, these markers (including some whose naming wrongly implies fibroblast specificity, for example, fibro blastspecific protein 1 (FSP1)) 84 may not be uniquely or continuously expressed, and they do not, therefore, pro vide a means for reliable tracking of the differentiation history of mesenchymal cells.
Basic studies of cell fate in chick 25 and mouse 4, 85 embryos using genomeintegrating viruses and trans geniclineage markers, respectively, were key to the demonstration that early populations of cardiac fibro blasts are derived from the proepicardial organ. More recently, genetic fatemapping tools have contributed to new insights into fibroblasts in the adult heart, includ ing in disease. Using Creexpressing lines and a colla gen1α1-green fluorescent protein (GFP) fusion reporter, the majority of fibroblasts in a mouse model of fibrosis, induced by pressure overload, were shown to be derived from cells resident in the heart, mainly from epicardial sources 86 . Concurrently, a study in which mice express ing TBX18-Cre, TIE2-Cre and PAX3-Cre were used to determine the origin of fibroblast lineages came to a similar conclusion -although a minor contribution by neural crestderived cells was also noted 55 .
A twist was recently added to this story, in which Cre-loxP technology was used to track epicardial and bone marrowderived mesenchymal cells 87 . Although pressure overload did indeed trigger the differentiation of fibroblasts, predominantly from resident EPDCs, in these experiments, collagen deposition and scar for mation following MI was determined by interactions between cells originating from both the bone marrow and the proepicardium. This study further suggested that regulatory interactions between the two different mesenchymal populations determined the transition to pathological levels of fibrosis -although it did not pro vide data that directly supported this interesting hypoth esis. Notably, this report used WT1-Cre, which, because of its activation at the earliest stages of proepicardial differentiation, tags a range of cardiac cells, largely with nonmyocyte phenotypes.
However, the conclusions of this work 87 support earlier studies that detected haematopoietic contri butions to mesenchymal cell populations in the heart, including to postMI scar formation 88, 89 . These reports were based primarily on chimeric mouse models, wherein genetically tagged (for example, with GFP) bone marrow cells were transplanted into irradiated (bone marrow incompetent) animals. The tag was then used to trace the fate of marked cells. Using this method, it was estimated that 28-57% of fibroblastlike cells in postMI scar tissue were of bone marrow origin, with a third of these cells adopting a myofibroblastic phenotype.
In a noteworthy extension of this experimental approach, haematopoietic stem cells were evaluated in vivo in a clonogenic manner by repopulating lethally irradiated murine recipients with a single GFPmarked bone marrowderived stem cell clone 89 . Following sur gically induced MI, clonally derived GFPexpressing cells were found to densely populate postMI scars. which the inflammatory response was already largely resolved (although resident macrophages would still be present). Bone marrowderived fibroblasts or myeloidderived fibroblasts (also known as fibrocytes) are recruited to injured loci as monocytes from the blood by the stromal cellderived factor 1α-CXC chemokine receptor 4 signalling axis 90 . These cells undergo a further transi tion to CD45 + mesenchymal cells under the influence of cytokines, including IL6 and monocyte chemoattract ant protein 1 (MCP1). Myeloid fibroblasts contribute to nonadaptive cardiac fibrosis and adverse remodelling, Figure 1 | The changing focus of cardiac fibroblast research in the past 50 years. Initially, cardiac research focused solely on histoanatomical investigations (indicated by black in the figure). Research then began to include the exploration of biophysical functions (blue), biochemical signalling (dark red), the potential for fibroblasts to contribute to cardiomyocyte transdifferentiation (green) and, most recently, the possible utility of targeting cardiac fibroblasts by clinical interventions (orange). These phases of research have given rise to a surge in publication activity and interest, as illustrated by a steep rise in citations to work in this area. Blue bars indicate the annual number of citations to papers listed on Web of Science containing the title terms 'cardio* AND fibro*'. For comparison, the red line indicates the underlying trend for increased publication activity, including all papers containing the title term 'cardio*'. This illustrates the pronounced and above-average increase in attention paid to cardiac fibroblasts in the past 20 years. Select key publications are indicated with coloured circles in the figure; the colours correspond to the research areas. The reference for each of these publications is indicated next to each circle. Early papers include a histological study of epicardial differentiation that indicated an extracardiac origin for epicardium 26 ; the in vitro electrophysiological demonstration of fibroblast-mediated synchronization of distant cardiac myocytes, illustrating heterocellular electrotonic cell coupling 239 ; a histological and ultrastructural study of how endocardial endothelium generates cardiac cushion mesenchymal cells 281 ; the characterization of homo-and heterocellular gap junctional channels between isolated cardiac myocyctes and fibroblasts
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; and the demonstration of a role for transforming growth factor-β in epithelial-mesenchymal transition (EMT) in atrioventricular cushion tissue 283 . A second wave of research was precipitated by the confirmation that paracrine signalling by fibroblasts represents a novel growth mechanism for myocardium 284 , and includes the identification of mechanosensitive fibroblasts in the sinoatrial node region of rat heart and the first quantitative modelling of their potential influence on cardiomyocyte electrophysiology 285 ; a cell lineage study demonstrating the presence of an epicardial origin for cardiac fibroblasts and smooth muscle cells 25 ; an illustration that epicardial EMT is regulated by different signalling pathways compared to endocardial EMT 286 ; and the demonstration in an animal model that statins can reduce cardiac fibrosis 172 . The next surge in articles followed an early report of a clinical trial involving intracoronary infusion of bone marrow-derived mesenchymal cells to treat acute myocardial infarction (MI) 287 , and includes the safety results from a clinical trial studying effects of intramyocardial infusion of bone marrow-derived mesenchymal cells on severe heart failure 288 ; a quantitative characterization of fibroblastmediated passive conduction of excitation between otherwise separated groups of cardiomyocytes in structured cell cultures 240 ; proof of in situ fibroblast-myocyte coupling in native rabbit sinoatrial node tissue 20 ; a cell lineage study demonstrating haematopoietic stem cell contribution to valve fibroblast populations 289 ; and a cell lineage study demonstrating that bone marrow-derived cells contribute to fibroblasts and myofibroblasts at myocardial infarcts 88 . The Nobel prize-winning discovery that pluripotent stem cells can be induced from mouse embryonic and adult fibroblast cultures by four defined transcription factors 100 and the realization that cardiac fibroblasts may themselves form a clinically relevant target for therapeutic interventions preceded the most recent wave of activity. Notable papers in this wave include an illustration of trans-scar electrotonic action potential propagation in rabbit left-ventricular infract tissue 265 ; the demonstration that engraftment of connexin 43-expressing non-excitable cells into murine scar tissue can prevent post-MI arrhythmogenesis 270 ; work establishing microRNA-29 as a regulator of cardiac fibrosis and a potential therapeutic target for management of tissue fibrosis 207 ; the demonstration that fibroblasts are essential for the adaptive response of the heart to pressure overload 215 ; confirmation that fibroblasts can be transdifferentiated into myocytes by defined transcription factors 102 ; and a cell lineage study demonstrating the primary contribution of resident cardiac fibroblasts to pressure overload induced fibrosis 86 .
particularly postMI and during ischaemic cardiomyo pathy, heart failure and ageing 90, 91 . In this context, TNF signalling, which regulates the transition of macrophages from an M2 phenotype (that is, immunosuppressive, proangiogenic macrophages) to fibroblastlike cells, could be particularly relevant, as has been shown in models of heart disease 92 . Finally, endothelial cells in the adult heart may undergo EndoMT and contribute to fibrosis after myocardial injury 93 . In this process, endothelial cells lose their endothelial identity and acquire mesenchy mal or myofibroblastic markers, such as expression of αSMA and secretion of type I collagen. Similar to EMT, EndoMT can be regulated by TGFβ 93 . Interestingly, recent studies suggest that this process can also be reversed, and that mesenchymal cells can generate coronary vascular endothelial cells by mesenchymalendothelial transition in a p53dependent manner 94 . Thus, the available evidence suggests that three main cell populations contribute to fibrosis after injury or in pathologic conditions in the adult heart: resident fibroblasts derived from EPDCs, mesenchymal pop ulations originating from circulating precursors and cells that have undergone EndoMT (FIG. 2) . There may also be a fourth minor contribution from the neuro ectoderm 55 . EPDCs seem to be the major contributor to fibroblast cell numbers overall, but ongoing studies may well uncover diseasespecific responses by different lineages, including regulatory interactions between the different mesenchymal populations that vary according to pathology.
Work on targeting or using mesenchymal cells for treating cardiac disease is broad and intensive 95 . Key foci of current translational research in this context are on regenerating heart muscle that was lost to disease by reprogramming fibroblasts to transdifferentiate into cardiomyocytes, and on reducing fibrosis or the extent of pathologic scarring that occurs in response to injury and/or disease
.
Fibroblast reprogramming in cardiac repair
Fibroblast reprogramming falls into the burgeoning field of regenerative medicine. Whereas the adult mamma lian heart repairs by forming a scar, amphibians and fish can regenerate injured myocardial tissue 96, 97 . There have been numerous tantalizing hints that therapies could be developed that recapitulate or simulate regenerative processes similar to those occurring in lower vertebrates, most recently from studies of reparative responses in newborn mice 98, 99 . The rationale for exploring whether fibroblasts can be reprogrammed into myocytes as a cardiac regener ation strategy can be traced back to the Nobel prize winning discoveries of Yamanaka and colleagues 100 . They reported the generation of iPSCs from somatic cells by retrovirusmediated overexpression of a combination of four transcription factors -OCT4, SOX2, Krueppel like factor 4 (KLF4) and MYC 100 . Subsequently, it was shown that forced expression of lineagespecific factors could reprogramme cells into defined phenotypes, with out reverting to an intervening stem cell 101 . In cardiac biology, GATA4, myocytespecific enhancer factor 2C (MEF2C) and TBX5 (collectively referred to as GMT) are sufficient to prompt the transdifferentiation of murine cultured fibroblasts into cardiomyocytes with early ontogenetic traits 102 . The GMT cocktail -sub sequently extended by adding a fourth transcription factor, the heart and neural crest derivativesexpressed protein 2 (HAND2) -improved cardiac function in a murine model of MI 103, 104 . In parallel, microRNAs (miRNAs) were shown to reprogramme cardiac fibroblasts into cardiomyocytes in vitro and in vivo 105 . Priming of EPDCs with the actin binding peptide thymosin β4 also triggers trans differentiation of these cells into myocytes -albeit at very low frequency 106 and potentially not in clinically relevant settings 107 . The path to cardiac reprogramming has not been smooth. In a replication study, the GMTinduced con version of fibroblasts into cardiomyocytes was relatively inefficient 108 . This work also indicated that the electro physiological phenotype of converted fibroblasts might not align with that of cardiomyocytes. Methodological differences between studies may underlie these variable observations. For example, vectordependent imbalances in protein expression of GATA4, MEF2C and TBX5 have been proposed as one reason for studytostudy varia tion 109 . A further impediment to translation may come from the finding that human cardiac fibroblasts seem to be resistant to reprogramming by GMT, although they may convert at low efficiency to immature beating myocytes if GMT is combined with HAND2, myocardin and two musclespecific mi RNAs: miR1 and miR133
Ongoing work on fibroblast reprogramming has focused on improving its reliability, safety and effi ciency. These efforts include: the optimization of the stoichiometry of factors in the reprogramming cocktail 109 ; identification of combinatorial miRNA treatments 111 ; development of delivery methods other than genome integrating retroviruses 112 ; and attempts to generate spe cific cardiac phenotypes, including atrial, ventricular and pacemaking cells 113 , with the longterm aim of producing cells with adultlike structural and functional properties. In addition, manipulation of cell transduction pathways, including those associated with TGFβ 114 and AKT1 sig nalling 115 , could increase the efficiency of cell reprogram ming. Enhancing AKT1 activation notably increased the efficiency of fibroblasttomyocyte conversion in vitro 115 . Interestingly, thymosin β4, which activates AKT, has been reported to enhance function postMI in the presence of GMT reprogramming 103 .
Novel drugs and biologics
Partial recovery of diseaseinduced changes in structural and functional tissue properties (reverse remodelling) is a target of clinical interventions 116 , in part because fibrosis is an independent predictor of arrhythmogen esis and sudden death in patients 117, 118 . Several estab lished pharmacological therapies that are known to reduce arrhythmias or the progression of heart disease affect connective tissue, including ACE inhibitors, 1, 3, 6 . Novel cardio protective therapies are being developed that preserve myocardial muscle, thereby inhibiting its replacement by scar tissue in the acute phase following cardiac injury. In addition, interventions, including cell thera pies, may provide cardioprotection and also enhance the ongoing woundhealing response of damaged hearts. Pharmacological approaches are also being developed to target chronic pathologic processes that lead to the accumulation of fibrotic tissue and heart failure. All of these approaches are discussed in detail below.
Cardioprotection. The single most important contribu tion to reducing the fibrotic burden in ischaemic heart disease in the past 25 years has come from the advent of reperfusion procedures such as angioplasty and anti platelet and antithrombotic medications, which restore blood flow to ischaemic myocardium in the immediate aftermath of a MI 119 . Myocyte viability is critically dependent on the availability of sufficient oxygen, and thus swift reestablishment of coronary vascular flow following a MI increases the survival of myocardial cells, thereby reducing postinfarction fibrosis. Although these procedures have revolutionized the critical care of patients after MI, the generation of reactive oxygen species associated with reperfusion can itself cause dam age to the heart. This is known as ischaemia-reperfusion injury, and it results in diminished contractile function and increased risk of arrhythmia 120 . Ischaemic preconditioning is a technique in which repeated short episodes of hypoxia reduce infarct size upon subsequent MI 121 . This technique has inspired the search for therapeutic approaches that take advantage of, or mimic, this cardioprotective effect, in particular in the crucial 1-3 hour window following coronary arterial occlusion 122 . An important step in the search for clinically Figure 2 | Cardiac fibroblasts and myofibroblasts in health and disease. Cardiac fibroblasts originate from various sources, including the epicardium, cardiac endothelium, neural crest and bone marrow. They form a multiplicity of cells that are important for cardiac structural and functional homeostasis. Cellular subpopulations, their precise precursors (both resident and circulating), their relationships with pericytes, as well as many aspects of their functional relevance are yet to be established. During pathology (but also upon cell isolation and culture), fibroblast activation by stimuli including stretch, hypoxia and inflammation can lead to phenotypic conversion through protomyofibroblasts to myofibroblasts. The presence and mechanisms of inactivaton of cardiac myofibroblasts are under investigation. EMT, epithelial-mesenchymal transition; EndoMT, endothelial-mesenchymal transition.
useful cardioprotective strategies has been the recent agreement on standardized animal models for preclinical screening 123 . In addition to classic preconditioning, car dioprotection can also be induced by temporary hypoxia at body locations other than the heart (for example, a limb) before MI (remote preconditioning) 124 or acutely following MI (postconditioning) 125 , or by subjecting the heart to mechanical stretch 126 . The processes induced by preconditioning may also contribute to the beneficial cardiovascular effects of regular exercise.
Novel approaches to pharmacologically induce cardio protection include targeting signalling through mitochon drialassociated protein kinase C and its substrates, such as aldehyde dehydrogenase 2, which reduces ischaemic damage by reactive aldehydes 127 . Compounds inhibiting the mitochondrial permeability transition pore (mPTP) may also mitigate changes that initiate mitochondrial driven cardiomyocyte death 122, 128 . This being said, the mPTP blocker cyclosporine A recently failed to meet endpoints in the CIRCUS trial -a study designed to determine whether this inhibitor protected hearts from ischaemia-reperfusion injury 129 . Other experimental and clinicalstage therapeutics that may mimic pathways acti vated in ischaemic preconditioning include phosphodi esterase 5 inhibitors (such as sildenafil (Viagra; Pfizer)) 130 , chloride channel and transporter modulators 131 , hydrogen sulfide 132 , rapamycin 133 and nitric oxide (NO) donors 134 . Overexpression of extracellular superoxide dismutase has been shown to increase NO bioavailability and provide cardioprotective benefit in transgenic mouse models 135 . Connexin hemichannels (known as connexons) are singlemembrane channels in transit to docking within gap junctions. Hemichannels have recently come into focus as another novel determinant of acute injury severity following MI 136, 137 . The majority of hemichan nels in the cardiomyocyte cell membrane are in a zone surrounding the gap junction called the perinexus 138 . In response to an ischaemic insult, hemichannels activate, opening nonselective pores that discharge high con centrations of proinflammatory, profibrotic molecules, such as ATP, while admitting cytotoxic levels of Na 2+ and Ca 2+ into cells 137 . There is also evidence that Cx43 hemichannels act in concordance with mPTP channels in response to ischaemic injury 139 . The short peptides Gap19, Gap26, Gap27 and αcarboxy terminus 1 (αCT1) all mimic key functional domains of Cx43 and have all been shown to inhibit hemichannel activity (Gap26 and Gap27 also block gapjunction channels) 140 . Gap19 has cardioprotective effects, substantially decreasing infarct size in a mouse MI model 137 . Gap26 confers cardioprotec tion postinjury in a rat MI model in vivo: intraarterial injection of the peptide 30 minutes after coronary artery ligation reduced infarct size by 61% 136 . Interestingly, the same experimental hemichannel blockers have proved effective in reducing glial scarring, providing neuropro tection following ischaemic stroke in animal models 141 .
Cell therapies. Mesenchymal stromal cells, haemato poietic and endothelial progenitor cells, as well as mononuclear cells that are derived from bone marrow and other sources, are at the core of a concerted effort in experimental reparative therapy development 142, 143 . Supported by preclinical studies in animal models, several groups have tested cell therapies in patients with MI. Many, but not all, trials reported modest increases in ejection fraction or other signs of functional improve ment, and some metaanalyses suggest that cell therapy with bone marrow mononuclear cells or mesenchymal cells may assist in the recovery of function of injured or diseased hearts 142, 144 . However, thus far, analyses have been based on small or moderately sized clinical investigations. Given the heterogeneity of both the cell preparations used and the patient populations studied, such analyses should be interpreted with caution 145 . The US ClinicalTrials.gov website lists more than 300 trials involving cardiac cell therapy, the majority of which are early Phase I and Phase II safety and efficacy studies. Outcomes from Phase III clinical trials involving thousands of patients are not yet available, but such results are necessary to establish whether haematopoietic or mesenchymal popu lations that consist primarily of bone marrow or adipose tissuederived cells reliably provide clinically meaning ful improvements, on top of current standard of care. A further note of caution on these therapies came from metaanalyses of the effects of intracoronary cell therapy on ischaemic heart disease (such the ACCRUE review of 12 randomized clinical trials). These metaanalyses failed to identify patient benefit, in terms of either clinical events or improved left ventricular function 146 . Cardiac stem cells have been suggested to be, or at least include, resident progenitor cell populations in the heart, with potential roles in regenerating myocar dium 147 . Various surface antigens such as the tyrosine protein kinase cKIT (also known as SCFR, KIT or CD117) and stem cell antigen 1 (SCA1), or spheroid cultivation assays, have been used to isolate cardiac stem cells. Engraftment of different cell populations improves cardiac function and reduces infarct area in mouse models, and two firstinhuman clinical trials assessing cKIT + cells (the SCIPIO trial) 148 and cardiosphere derived cells (the CADUCEUS trial) 149 reported prom ising results. However, the contribution of cardiac stem cells to regeneration of the heart is still a matter of debate, as is the potential for heart muscle cells to con tribute to selfrepair by proliferation 150 . Whereas mouse heartfailure models have suggested that resident cKIT + cells may affect cardiac repair by direct cardiomyogenic contributions 151 , Crereporterbased experiments have demonstrated that cKIT expression is largely confined to nonmyocyte cardiac lineages 152 . The latter finding is consistent with other reports, which found that the cardio genic potential of cKITexpressing cells in the adult heart is limited 153 , and that cKIT predominantly labelled cardiac endothelial cells in developing and adult hearts 154 .
Another study suggested that the majority of cKIT derived muscle cells were preexisting cKITexpressing cardiomyocytes rather than cells formed de novo from cardiac stem cells 155 . Similarly, lineage tracing of SCA1 + stromal cells revealed only a modest contribution of these cells to cardiovascular lineages after injury and during ageing 156 .
Unfortunately, the debate on cardiac cell therapy has, in a few highprofile cases, moved beyond scien tific controversy 157 . The emphasis of the field has also shifted from regeneration to the potential cardiopro tective effects of cell therapies -effects that, in large part, are now thought to be mediated by paracrine mechanisms. This view is consistent with the fact that many of the paracrine factors released by the applied cells are known to influence fibrosis, angiogenesis and inflammation, and, by these means, affect cardiac heal ing responses and scar properties 158 . Matrix remodelling can be influenced by the release of matrixmodulating enzymes, such as matrix metalloproteinases (MMPs) 159 , or by modulating the expression of tenascins 160 . The secretion of hepatocyte growth factor (HGF) 161 , adreno medullin 162 and thymosin β4 (REF. 163 ) may also directly affect cardiac fibrosis. Interleukins may act to inhibit cardiac fibroblast proliferation and collagen produc tion as well as myofibroblast differentiation 164 , whereas mesenchymal stromal cellderived leptin was shown to inhibit fibroblast activation by blocking pathways involv ing TGFβ-SMAD and myocardinrelated transcription factor A 165 . Detailed analysis of bone marrow mononuclear cell secretomes has led to the identification of novel cardio protective proteins, such as myeloidderived growth factor 166 . In addition to secreted proteins and growth factors, cells of different origins can release extracellu lar vesicles, such as exosomes, which contain various bioactive molecules, including miRNA 167 . Thus, cell therapies may profoundly alter the paracrine microenvi ronment in the healing heart, thereby not only affecting mesenchymal cell activity and transdifferentiation, but also enhancing regeneration, potentially by inducing cardiomyocyte proliferation 168 (albeit at rates as low as 1% in 25 years) 150 . However, the low homing and survival rates of exter nally applied cells in scar tissue are likely to limit the duration of paracrine protective actions 169 . Augmenting homing and survival -either by pretreating the engrafted cells with prosurvival factors, genes or miRNA, or by preconditioning the target tissue -may enhance the efficacy of cell therapy 169 . With ongoing development of the field, it will be interesting to see whether cellfree cocktails of bioactive molecules can be formulated that supersede cellinjectionbased therapies 170 . Antifibrotic therapies. Congestive heart failure, a pro gressive and ultimately incurable disease, is marked by the increasing inability of the ventricle to pump blood sufficiently to meet the demands of the body. Replacement of cardiac muscle by fibrotic tissue is thought to be at the pathogenic nidus of heart fail ure 1, [3] [4] [5] [6] . The acute loss of muscle, such as that sparked by MI, viral infection or drug toxicity, could be the precipitating cause of heart failure and is followed by disease progression. Fibrosis at interstitial and perivas cular locations in the failing ventricle can also occur as part of longerterm processes that are associated with ageing or diseases, such as hypertension, aortic steno sis, metabolic disease and obesity. In the atria, con nective tissue accumulation is an underlying cause of atrial fibrillation. Preventing, or at least inhibiting, the accumulation of pathologic levels of fibrotic tissue in both ventricular and atrial myocardium is thus a major therapeutic goal.
Exploration in this area is focused on antifibrotic activities of established drugs and on novel compounds. Examples of the former category include statins, which are anything but new and are among the most widely prescribed drugs of the past quarter century. The pri mary mode of action of statins is to lower cholesterol levels through inhibition of 3hydroxy3 methylglutaryl coenzyme A reductase 171 . It has emerged from preclin ical and clinical studies that certain statins also inhibit scarring, fibrosis and adverse myocardial remodel ling [172] [173] [174] . The mechanism through which statins inhibit fibrosis is not entirely clear, although simvastatin inhibits transdifferentiation of cardiac fibroblasts into myo fibroblasts, an effect that is overcome by application of TGFβ 175 . Other established drugs that have antifibrotic actions include aldosterone antagonists and angiotensin receptor and ACE inhibitors 3 . A number of recent reviews have summarized pre clinical and clinical progress on novel therapeutics, so these topics are only briefly covered here 1, [3] [4] [5] [6] (TABLE 1) .
Experimental or clinicalstage antifibrotic compounds include TGFβ pathway inhibitors [176] [177] [178] [179] [180] [181] , MMP inhibi tors 10 , inhibitors of mast cell function 182, 183 , monoclonal antibodies neutralizing MCP1 (REF. 184 ), CXC chemokine ligand 10 (CXCL10; also known as γIP10) 185 , endothelin pathway inhibitors 186 , ANGII pathway inhibitors 187, 188 and modulators of WNTsignalling 189, 190 .
Box 1 | Effects of fibroblasts on cardiac physiology
Fibroblasts affect numerous aspects of cardiac form and function, including:
• Histoanatomy -Adaptive fibrosis -Remodelling of the extracellular matrix (ECM) -Changes in tissue stiffness -Contributions to heart failure
• Biophysical signalling -Alterations in connexin localization and function -Altered conduction, including action potential propagation into scar tissue -Increased quantities of ECM, which acts as an electrical insulator, thereby reducing electrical connectivity
• Biochemical signalling -Adaptive hypertrophy -Increased inflammation through the recruitment of circulating lymphocytes -Apoptosis, resulting in muscle loss
• Cell differentiation -Possible fibroblast-myocyte transdifferentiation -Endothelial-mesenchymal transition or epithelial-mesenchymal transition -Fibroblast effects on the microenvironment through paracrine signalling
These fibroblast-related changes may be harnessed to better regenerate or repair heart muscle. For example, fibroblasts could be targeted in patients with atrial or ventricular fibrillation to prevent disease progression and to improve the efficacy of catheter ablation. Alternatively, they could be targeted to make scars 'electrically invisible' in patients who have had myocardial infarctions, hence making the scars less arrhythmogenic.
Other new antifibrotic targets include the proto oncogene SKI, the basic helix-loop-helix transcription factor scleraxis and the cell membrane proteins β3 inte grin and caveolin 1. SKI inhibits TGFβ signalling by binding to downstream transcriptional regulatory pro teins in the TGFβ-SMAD pathway 191 . Overexpression of SKI in isolated cardiac myofibroblasts was found to result in phenotypic reversion, marked by reduced collagen expression and myofibroblast contractility 192 . Scleraxis is a key regulator of collagen synthesis in cardiac fibroblasts, with potential regulatory roles in fibroblast to myofibroblast differentiation 193 . Mice deficient for β3 integrin showed substantial decreases in pressureoverloadinduced fibrosis, suggest ing the involvement of this integrin in maladaptive ECM accumulation 194 . By contrast, loss of caveolin 1 function in mice following MI 195 and in isolated human atrial fibro blasts 196 resulted in TGFβ1associated fibrosis and upreg ulation of profibrotic genes. Although the path to clinical translation of SKI, scleraxis, and β3 integrin to druggable targets is still in the exploratory phase 197, 198 , peptidergic drugs targeting caveolin 1 function have demonstrated promise as antifibrotic therapeutics in studies of lung fibroblasts from scleroderma patients 199 . Relaxin 2, a neurohormone historically linked to preg nancy and parturition, is another novel biologic compound that has made the translational jump from basic research to the clinic (under the generic name serelaxin), and it has had efficacy in clinical testing of patients with acute heart failure 200, 201 . The large placebocontrolled Phase III trial of relaxin 2 (RELAXAHF, which enrolled 1,161 patients with heart failure) reported significant improvements in patient symptoms as well as decreases in the length of their hospital stays and increased survival rates 202 . It is presently unclear what molecular mechanism underlies the effect of relaxin on fibrosis. However, experiments in cell culture models indicate that relaxin inhibits and/or reverses myofibroblast differentiation induced by ANGII and TGFβ, as assessed by changes in gene expression and markers of cellular electrophysiology 203, 204 . A number of miRNAbased strategies have also recently shown potential for inhibiting cardiac fibrotic processes 205, 206 . The first matrixregulating miRNA to be identified in the heart, miR29, targets several matrix pro teins, including collagens 207 . Overexpression of miR29 in cardiac fibroblasts reduces collagen expression, albeit modestly 207 . Antagomirmediated silencing of miR21 in vivo inhibits interstitial fibrosis and attenuates dysfunc tion in a murine ventricular pressureoverload model 208 . Similarly, knockdown of miR21 by antisense RNA in the atria was found to suppress atrial fibrosis in a rat model of MIinduced heart failure 209 . However, in other studies, lockednucleicacid antimiRbased inhibition of miR21 or genetic deletion of the gene encoding miR21 failed to block the adverse ventricular remodelling response of mouse hearts subjected to pressure overload 210 . Differences in the antifibrotic response may in part rely on the chemistry that was used to inhibit miR21 (REF. 209 ). Although the antifibrotic activity of antimiR21 in the heart is debated, a modified antisense targeting miR21 (named RG012) is currently being clinically tested in patients with kidney fibrosis (the ATHENA trial) 211 . Many additional mi RNAs control myocyte survival after MI, thereby indirectly or directly affecting fibrosis 212 . Inhibition of ageinduced miR34 expression can also decrease agerelated cardiac fibrosis 213 . Interestingly, miRNA may not only directly or indirectly target fibroblasts; it is also released by cardiac fibroblasts. For example, fibroblastderived exosomal miR213p (also known as miR21*) acts as a potent paracrineacting RNA molecule that induces cardiomyocyte hypertrophy 214 . All in all, present conceptual approaches for therapeu tic interventions are focused on avoiding or inhibiting fibrosis and/or on turning nonmyocytes into working cardiac muscle. An alternative idea, providing a lower hanging fruit of potentially high value, is discussed below: the creation of better scars 2 .
Re-engineering scars Using the natural reparative processes of fibroblasts to modify properties of the forming cardiac scar is quietly emerging as an exciting therapeutic avenue. Part of the rationale here comes from the recognition that, although fibrotic responses are common in the repair processes in the human heart, not all fibroblastmediated cardiac remodelling is detrimental 36, 83, 215 . Fibroblast lineage studies already hint at differences in regulatory interactions that determine fibrosis in response to ischaemic versus hypertrophic diseases 87, 90, 91 . Furthermore, fibroblasts in the atrium and ventricle show differences in gene expression 216 , electrophysio logical characteristics 74, 217 and propensity for profibrotic activity 218, 219 . Cardiac scar formation is not always the result of disease. Interventions such as catheter ablation therapy intentionally generate scars in the heart to obliterate reentrant activation pathways, for example to alleviate atrial rhythm disturbances 220 . In addition, paediatric cardiologists face the growing (and in some ways welcome) problem of managing adult patients with morbidities that are linked to the accumulation of scar tissue resulting from childhood surgeries to correct heart birth defects 221 . It is important in this context to recall that not all car diac scars are created equal. Postsurgery, de novo genera tion of both ECM and cellular content are involved in scar generation, whereas postablation scars are recellularized on the background of preexisting ECM. PostMI scars, by contrast, contain not only native ECM but also sur viving heart cells of different types, albeit with reduced myocyte content, caused by the pronounced sensitivity of these cells to oxygen starvation. These present three potentially quite different pathophysiological settings.
The ability to personalize the properties of cardiac scar tissue to meet the needs of different types of scar and patient is thus an interesting and currently unmet clinical need 2, 222 . Therapeutic potential of modifying scar mechanics. Notable aspects of the effort to engineer a better scar include insights into biomechanical inputs in fibrotic tissue differentiation as well as the role of scar structure in determining the efficiency of cardiac output. Ventricular function has recently been recognized to be affected more by the alignment of collagen fibres within postMI scars than by scar stiffness or collagen density 223 . Collagen alignment, in turn, is a function of mechanical stress patterns that cardiac scars are subjected to during the contraction cycle.
Scar mechanical properties are also crucial factors for the genesis of complications arising from ischaemic heart disease -including infarct rupture and scar expan sion -that can occur after MI. Experimental therapies that attempt to modify mechanics and inhibit patho logical remodelling of the infarct include mechanical restraints that limit or direct the motion of scars during the heartbeat 224, 225 , injection of polymers to modify scar rigidity [226] [227] [228] , MMP9 lossoffunction mutations 229 and hydrogels containing tissue MMP inhibitors (or viruses overexpressing them) 230, 231 . It is also of note that cardiac resynchronization therapy, an approved treatment for dilated heart failure, can promote reverse remodelling by normalizing regional stress and/or strain patterns across the infarcted ventricle 232 . The risk of postMI scar dilation and rupture is an important safety consideration for therapies targeting scar mechanical properties. The ventricle of the adult human heart generates systolic pressures of 120-180 mmHg, sim ilar to mice and rats postpartum, but nearly one order of magnitude higher than pressures in utero (~30 mmHg) and about two orders above that of animals in whom myocardial regeneration is maintained into adulthood, such as the zebrafish (~2 mmHg) 233 . It seems a reasona ble conjecture that the evolutionary emergence of higher blood pressure in adult mammals may have had an impact on the risks and benefits of healing the heart by scarring versus regeneration. In an illustration of this potential tradeoff, adult mice in which the gene encoding the ECM protein periostin (Postn) has been knocked out are prone to ventricular rupture following MI 65, 234 . However, those Postnknockout mice that survived exhibited reduced levels of scarring and improved cardiac performance 65 . One might expect that therapies based on cardio myogenic stem cells also pose increased risk of rupture and ventricular dilation, wherein infarcts could be more likely to show mechanical failure when healing is shifted towards regeneration and away from expeditious forma tion of a mechanically strong scar. Bone marrowderived cells, which have limited cardiomyogenic potential, may be beneficial in this respect. Pharmacologically induced increases in recruitment of bone marrowderived mes enchymal progenitor cells to MI in a mouse model was reported to be associated with reduced rates of ventricular rupture and death 235 . These effects may provide a further explanation for how bone marrowderived cell infusion contributes to clinical improvements following MI, and they also suggest novel strategies to manipulate these cells so that they homein on infarcts and generate better scars. In an example of this approach, a lentivirus express ing a smallhairpin RNA (shRNA) that targets periostin was injected into femur bone marrow before ventricular injury. This shRNA treatment was reported to reduce scar size and improve cardiac function without ventricular rupture, which occurs following MI in mice with a global knockout of Postn 236 . In this experiment, Postn knock down was limited to bone marrow cells migrating to the MI, suggesting that selectively decreasing periostin expression in this extracardiac cell population may pro vide a therapeutic path to reduce scarring, and possibly promote regenerative healing, following cardiac injury.
Therapeutic potential of modifying scar electrical properties. Fibrous, collagenrich tissues in the heart have traditionally been viewed solely as nonconducting and electrically insulating structures. Undoubtedly, that is one of the most relevant functional effects of fibrosis, as observed more than a century ago 237 . However, newer data have led to a more nuanced understanding of the electrical properties of cardiac scars and the implica tions of the electrical interaction between myocytes and nonmyocytes 7, 22, 238 . Since the 1960s, it has been known that fibroblasts and myocytes can couple elec trically in vitro 239 , and more recently it was confirmed that cultured fibroblasts can bridge the transmission of action potentials between otherwise separated clusters of myocytes across gaps of up to 300 μm 240 . In an analo gous example from the clinical literature, 10-20% of heart transplant recipients have been reported to develop electrical coupling across scar tissue at suture lines sepa rating donor and recipient heart tissue 241 . Similarly, elec trical conduction across fully transmural scars can be seen after surgical correction of cardiac birth defects 242 . Myocyte-fibroblast coupling may occur through connexinbased gap junctions 21, [243] [244] [245] , which are far from uncommon in native myocardium 246 . However, function ality of connexinbased fibroblast-myocyte coupling in native cardiac tissue has been corroborated so far only in rabbit sinoatrial node tissue 20 . Underlying structures may also involve filamentous projections made by mesen chymal cells, called tunnelling nanotubes, through which ions and small molecules can be directly exchanged 247 . Ephaptic conduction, a method to transfer currents between cells that does not use gap junctionbased coupling, has been reported between myocytes and could also have a role in myocyte-fibroblast coupling 248, 249 . In situ, cardiac fibroblasts exhibit complex and extended flat shapes with irregular folds and elongated cell processes 19 . To give a sense of their extended spa tial scale in vivo, cardiac fibroblasts are typically an order of magnitude larger in the intact heart than when freshly isolated 2 . Fibroblasts have membrane poten tials of between -10 and -50 mV and a relatively high membrane resistance 2 . Their extended morphology and elevated membrane resistance enhances their ability to act as passive, longdistance conductors of electrical signals in vivo, including action potentials, when cou pled to electrically active cells such as myocytes 243, 250 . In quantitative mathematical simulations of hetero cellular electrical crosstalk, performed in the 1990s using 'passive' fibroblast models, fibroblasts that were electrically coupled to muscle cells could affect cardio myocyte excitability, altering heart rate and rhythm 251 . More recently, based on emerging experimental insight into their electrophysiology, detailed ionic models of cardiac fibroblasts have been developed 252 . Modelling studies have since provided indications that myofibro blasts may have specific electrophysiological relevance for arrhythmogenesis 253 , a phenomenon that may relate to fibroblast-myocyte coupling and include changes in fibroblast membrane ion currents that occur following MI 2, 5, 7, [253] [254] [255] [256] . Both passive and active fibroblast models have been productive for theoretical assessment and hypothesis testing, at times preceding experimental validation [257] [258] [259] [260] . A major step towards more realistic com puter simulations occurred with the advent of detailed 3D scar reconstructions 261 , paving the way towards clini cally relevant prediction of scar effects on heart function. However, thus far, these studies have focused largely on the classic view of scars as electrical insulators [262] [263] [264] .
In an influential study, ventricular scars were shown to be capable of conducting electrical signals 265 : optically mapped action potential waveforms were observed to conduct into scar tissue in a rabbit transmural MI model. Infarct tissue continued to support conduction even after subendocardial muscle layers were chemi cally ablated, thus excluding the possibility of electrical contributions from surviving contiguous myocardium. This observation was followed by reports from other groups 266, 267 , indicating the possibility that nonmyocytes may serve as conduction pathways that link surviving myocyte islands inside postMI scar tissue, thus allowing transscar conduction. Further support for this theory was provided at a recent Keystone conference, where data were presented demonstrating Cx43dependent conduction into scar tissue in a fully transmural ven tricular injury in a transgenic mouse model 268 . Another group at this conference reported direct evidence of conduction into nonmyocytes of the scar border zone, using a fluorescent voltage reporter genetically targeted to nonmyocytes by the WT1 promoter 269 . Nonmyocyte based transscar conduction could be used in novel therapeutic approaches. If, in a clinical setting, scar tissue could be rendered electrically 'invis ible' with respect to the propagating impulse, then the potential for infarcts to cause lifethreatening arrhyth mias might be reduced. For example, engraftment of Cx43expressing cells into murine scar tissue prevents postMI arrhythmogenesis 270 . A peptide mimetic of αCT1 has been reported to reduce hemichannel activity and increase intercellular coupling by enhancing the recruit ment of undocked connexin hemichannels into gap junc tions 138 . Similar to the engraftment of Cx43expressing cells postinfarction 270 , treatment of mouse ventricular injuries with αCT1 reduced the incidence of arrhythmia and increased conduction velocity, including through the infarcted section of the ventricle 271 . Tissueengineered constructs containing cardiac myo cytes and fibroblasts have also been used successfully to conduct excitation from atria to ventricles in cases of experimental atrioventricular conduction block 272 . This is another potential therapeutic application that depends on efficient heterocellular coupling among tissue graft components and at the graft-myocardial interface, both of which involve propagation of electrical signals across nonmyocytes 238 .
The goal of engineering more conductive scars in postMI patients is contrasted by the need for certain types of scars to remain impenetrable to electrical inputs from surrounding myocardial tissues, such as in the con text of atrial ablation 220 . For this procedure, focal energy delivery -for example, from a radiofrequency catheter -is used to generate lesions that interrupt conduc tion of spurious excitation waves, thereby terminating atrial arrhythmias. Unfortunately, a large proportion of patients show reemergence of functional conduction across intraprocedurally established ablation lines 273 . Extrapolating from (and 'inverting') the electrophysio logical effects of Cx43 overexpression in postMI scar tissue, a decrease in connexin expression in atrial fibro blasts could potentially provide an approach to improv ing outcomes of atrial ablation procedures. Alternatively, one could build on an engineering approach in which Cx43expressing fibroblasts were first transfected to express voltagesensitive potassium channels, such as K v 1.3, and then engrafted into rat hearts 274 . These grafts of clustered mesenchymal cells were found to alter local electrophysiological properties, and, owing to their enhanced potassium current, they reduced automaticity and prolonged refractoriness of surrounding electrically coupled cardiac myocytes. This concept, pioneered in ventricular tissue, could be adapted to counter transscar conduction across atrial ablation lines.
Outlook
Research over the past 25 years has identified the cardiac fibroblast as a cell with an unexpected range of effects that integrates and organizes myocardial structure and function at various levels, from local signalling to global electromechanical function. There has been further insight into the wellestablished roles of fibroblasts in cardiac structure and ECM generation, together with an expanding appreciation of their paracrine effects, functions as mechanical and electrical signalling hubs, and roles in myocardial repair. There can be little doubt that there will be new surprising roles for fibroblasts in homeostasis and disease, but this is a suitable moment to take stock of this protean cell. By analogy to the glia of the central nervous system -which was once regarded as a trophic glue but is now recognized as a structure whose relevance for tissue function is on par with that of the neural network itself -we know too little about the relevance of nonexcitable cells in homeostasis of excitable tissues and organs. What we do know is that the replacement of excitable cells, whether by gliosis or fibrosis, is a chief element of pathogenic processes in diseases of the brain and heart.
It is time, therefore, to shift our appreciation of cardiac mesenchymal cells away from viewing them as a passive component in an integrated and dynamic tissue system -diverse in ontogeny and inseparable from the myocardial syncytium but otherwise secondary in rel evance -to one in which they are credited with active contributions to complex, multifunctional regulatory processes that are crucial not only for development but also for structural maintenance and functional operation of the heart. The concept that fibroblasts link together to form a cardiac subsystem of coequal importance to the syn cytial network of myocytes should inform our approach to targeting or using mesenchymal cells in therapies for heart disease. In this respect, there are a number of exciting opportunities and important ques tions. The implications of complex sets of intercellular interactions, both homocellular and heterocellular, are poorly understood, and modulating celltocell com munication in the heart through biochemical and bio physical factors may provide new therapeutic targets. Novel paracrine factors could be identified by analysing the secretome of cells -as has been done for cells used for cell therapy 166 . Recent studies suggest that among the many long noncoding RNA molecules, some may code for small peptides with potent biological activ ity 275 . Similarly, wellknown cardiac proteins such as Cx43 can generate alternative bioactive peptides in response to ischaemia by capindependent transla tion 276, 277 , peptidase processing 278 or as a docking motif for exosome-cell communication 279 , further suggesting the possibility of new regulatory molecules and mech anisms that have been overlooked so far. In addition to proteins and peptides 280 , metabolites (for example, lipids and metabolic intermediates) may be identified by new 'omics' tools as structural and functional reg ulators of the heterocellular heart. Development of pharmaceutically tractable compositions and delivery systems, including cellspecific targeting, are among the hurdles that must be overcome if these newly identified factors are to be harnessed as therapies for improving cardiac health.
Better markers and lineage tracing tools are needed for cardiac mesenchymal cells. Such tools would enable the exploration of the regulation of cell plasticity, allow ing insight into the heterogeneous origins of fibroblasts, processes such as EMT, EndoMT and mesenchymalendothelial transition (the reverse of EndoMT), and their various response patterns to physiological and pathophysiological challenges. Improved lineage tools may also provide us with the knowledge necessary for coopting fibroblast behaviours, such as homing to injured loci, as a treatment modality. One might envisage genetic modifications of these migratory cells to carry payloads to damaged myocardial tissues in personal izedmedicinetype approaches. Furthermore, the ability to more reliably trace cell fate would enable a more thorough understanding of the mechanisms underlying fibroblast reprogramming and cell therapies, thus mov ing us closer to being able to comprehensively repair and/or regenerate the damaged heart.
In the meantime, the more modest goal of modifying scar tissue for patient benefit seems to be a useful tangible objective. Humans and other mammals heal damaged hearts by scarring and fibrosis. We should take a cue from mother nature and determine how to therapeutically nudge or reengineer this process, in order to improve clinical outcomes for patients with heart disease. 
